摘要

<正>The whole field of hematological malignancies has experienced a huge breakthrough during the past 40 years. Major methodological progress in cytogenetics (e.g., fluorescence in situ hybridization, FISH), immunophenotyping (e.g., multicolor flow cytometers), and molecular biology (with the discovery of numerous tumor molecular markers by polymerase chain reaction and,